2025-10-09 マサチューセッツ大学アマースト校
<関連情報>
- https://www.umass.edu/news/article/umass-amherst-researchers-create-nanoparticle-vaccine-prevents-cancer-mice
- https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00488-4
- https://medibio.tiisys.com/132003/
プラットフォーム癌ワクチンのためのスーパーアジュバントナノ粒子 Super-adjuvant nanoparticles for platform cancer vaccination
Griffin I. Kane ∙ Tiana E. Naylor ∙ Ellis F. Lusi ∙ … ∙ Stefania Gallucci ∙ Katherine A. Fitzgerald ∙ Prabhani U. Atukorale
Cell Reports Medicine Published:October 9, 2025
DOI:https://doi.org/10.1016/j.xcrm.2025.102415
Graphical abstract
Highlights
- Lipid NPs carrying STING and TLR4 agonists promote synergistic type I interferons
- NPs drain efficiently to lymph nodes and increase polyfunctional T and B cells
- NPs improve tumor-free outcomes with memory against multiple aggressive tumor models
Summary
We report on the utility of a “super-adjuvant” nanoparticle (NP) system as a modular, customizable platform for next-generation cancer vaccination. Using nanomaterials engineering technology, we aim to harness not only the effective adjuvanticity of whole-pathogen vaccines, but also the safety of subunit vaccines. Our lipid-based NP platform co-encapsulates agonists of the stimulator of interferon genes (STING) and Toll-like receptor 4 (TLR4) pathways to promote synergistic production of type I interferons and other proinflammatory cytokines in innate antigen-presenting dendritic cells and macrophages. Compared to empty NPs and free agonists, dual-adjuvant NPs administered with antigenic peptides or tumor cell lysate promote increased antigen processing and presentation, drain efficiently to nearby lymph nodes, increase polyfunctional tumor-specific T and B cells, and improve tumor-free outcomes upon vaccination and subsequent challenge with multiple aggressive tumor cells.
